CRO & CDMO Partner
To be an in-depth & trust-worthy CRO & CDMO Partner
Scientific & Rigorous, in search of excellence
Innovation & Change,high-efficiency operation
Who We Are
Beijing Hope Pharmaceutical Co., Ltd., established in 2005, is a high-tech enterprise with "chemical drug technology development-Process Optimization-Regulation registration and approval" as its core competence, and has won the title of "China Top 20 Pharmaceutical R&D Company" for several times. Hope Pharma actively builds one-stop service for drug CRO and CDMO, continuously expands its service areas, and establishes good cooperative relations with some leading pharmaceutical companies domestic and abroad.
Hope Pharma has over 20 years of experience in project evaluation, innovation-oriented patent around design, pre-clinical development, clinical trial practice, registration, marker authorization, etc..Our products involve anti-tumor, anti-depressant, anti-epileptic, anxiolytic, cardiovascular and cerebrovascular, digestive system, respiratory system and other indications.
Until now, more than 140 technology transform, over 90 registration approvals and 68 patents has been finished in Hope(including subsidiaries) for past 20 years, and has been rated as a national high-tech enterprise.
Focus on medicine development
More than 140+ technology transfer succeeded
Over 68+ invention patents applied
More than 35+ series of products Industrial production
Milestones
-
2024
Awarded the title of 'National High-tech Enterprise' for 17 consecutive years Awarded the title of 'Top 20 Chinese Pharmaceutical R&D Companies' for 8 consecutive years Submitted registration applications for 10 formulation products in China, obtaining over 80 various registration approvals Obtained registration numbers for 10 active pharmaceutical ingredients from FDA, CDE, Taiwan Ministry of Health and Welfare, and other institutions Submitted 12 new patent applications, with a total of over 60 invention patents Achieved a cumulative factory technology transfer of over 130 items to client companies
-
2023
Awarded the title of 'National High-tech Enterprise' for 16 consecutive years Awarded the title of 'Top 20 Pharmaceutical R&D Companies in China' for 7 consecutive years Has obtained more than 70 clinical, production licenses, and new drug certificates approved by the National Medical Products Administration of China Has submitted more than 10 international registration applications to the FDA, EU, etc. Cumulatively achieved over a hundred technology transfers to client companies Completed multiple technology achievements transformation and industrialized production of over 30 series products
-
2022
More than 20 new invention patent applications Two raw material drug varieties registered with CDE transferred to A Five formulation varieties obtained production licenses Shanghai branch established to strengthen business expansion and layout
-
2021
Obtain the first CEP certificateObtain CNAS certification certificate First submission of MAH certification and obtain B certificate Two raw material drug varieties CDE transfer to A
-
2020
The R&D office building of Jinghai Industrial Park is officially in use. Establish a strategic partnership with Zezheng Pharmaceutical.
-
2019
The subsidiary Haimei Ocean was established, and international business operates independently. Submitted registration applications to the EU and FDA Ranked among the top 20 pharmaceutical R&D companies in China for consecutive years Pilot unit for integration of informatization and industrialization Won the T100 New Technology and New Product Innovation Action Enterprise Award
-
2018
Establish a strategic partnership with PPC Jiaseng Consecutively ranked among the top 20 pharmaceutical R&D companies in China
-
2017
Establish a strategic partnership with Boteng Pharmaceutical Awarded the title of one of the top 20 pharmaceutical R&D companies in China
-
2016
The subsidiary Haimeiyuan was established, and the CRO business operates independently.
-
2015
The subsidiary Haimeitong was established, and the raw materials and intermediates business operates independently. Establish an employee stock ownership platform and complete the shareholding system transformation.
-
2011
Investing in Shandong Kongfu Pharmaceutical
-
2008
Establish a strategic partnership with Beihua Hengye
-
2006
Establish a new drug research and development center
-
2005
Established Haibu Pharmaceutical
What we do
18
2024-12
16
2024-12
14
2024-11
Subsidiaries
Beijing HMT Medical Technology Co., Ltd.
API & intermediate business
Beijing HMY Medical Technology Co., Ltd.
CRO business
Beijing HMYA Medical Technology Co., Ltd.
International business
Beijing Hope Pharmaceutical Co., Ltd.
